A large set of markers can be attributed to this category: Satb2, Nrg1, PCP4, CHRDL2, and MFAP2—to combat all leiomyoma types; HMGA2, GRPR, PLAG1, PAPPA2, and MB21D2—to combat HMGA2-dependent leiomyoma; ADAM12, MMP11, MMP16, RAD51B, THSD4 (Adamtsl6-β), and RUNDC1—to combat the MED12-dependent leiomyoma types. This evidence concerns the gene HMGA2 and leiomyoma.